Orpheus

Ocean Innovation Highlighted at COP28 in Shared Commitment Between Prince Albert II of Monaco Foundation, OceanX, and the World Economic Forum's 1000 Ocean Startups

Retrieved on: 
Tuesday, December 5, 2023
Woman, Engineering, Organization, COP28, Climate, NASA, Orpheus, ROV, Prince, World Economic Forum, Health, Jet Propulsion Laboratory, Conference, JPL, Biodiversity, Woods Hole Oceanographic Institution, Forum, 3D, Clay, Propeller, Tourism, Renewable energy, Triton, OceanX

DUBAI, United Arab Emirates, Dec. 5, 2023 /PRNewswire-PRWeb/ --The Prince Albert II of Monaco Foundation, OceanX, and the World Economic Forum's 1000 Ocean Startups Coalition today celebrated two partnerships promoting ocean innovation during the 2023 UN Climate Change Conference (COP28) in Dubai, UAE.

Key Points: 
  • The World Economic Forum and OceanX's collaboration provides OceanXplorer's cutting-edge technology to ocean start-ups, supported by the Forum's 1000 Ocean Startups coalition (1000OS) to promote blue technology.
  • We are very honored to be joined in our mission by the World Economic Forum's 1000 Ocean Startups coalition.
  • "We are thrilled to partner with the World Economic Forum's 1000 Ocean Startups coalition to support and promote ocean technology and innovation that furthers our shared goal of creating global change for the ocean."
  • "OceanX and the Prince Albert II of Monaco Foundation are early champions in the field of ocean innovation.

One of 2023's Must-Read Novels Is Tales of a Spiritual Sun, a Collection of Short Stories That Combine Greek Mythology with Everyday Modern Heroes

Retrieved on: 
Monday, April 3, 2023
Narcissus, Myth, Delusion, Homicide, Nymph, History, Tony Kiritsis, Philosophy, Margaret Atwood, Amazon (company), Love, Orpheus, The Penelopiad, Heracles, Entertainment, Proteus, Hypersexuality

This innovative book combines the excitement and action of traditional Greek mythology with fresh settings, themes, and everyday modern heroes.

Key Points: 
  • This innovative book combines the excitement and action of traditional Greek mythology with fresh settings, themes, and everyday modern heroes.
  • Tales of a Spiritual Sun delves into the lives of favorites like Pandora without neglecting oft-overlooked characters such as Proteus or Psyche.
  • In a glowing review, Kirkus describes Tales of a Spiritual Sun as "skillfully written" with "an array of memorable players."
  • Tales of a Spiritual Sun is available for purchase on Amazon.com , olympiapublishers.com , and wherever books are sold.

Orpheus Skin Launches A New Bioactive Micro-Foaming Resurrection Serum Slip Cleanser

Retrieved on: 
Thursday, October 20, 2022
Cream, Skin, CELL, Growth, MSRP, THE, Biotechnology, Research, Instagram, SKIN, Antioxidant, Inflammation, Technology, Collection, NEW, Serum, Lactic acid, Glass, Founder, Hyaluronic acid, Orpheus, Amazon, Environment, DNA, Type I collagen, Elastin, Lipid, Magic, Damask, ORPHEUS, Cosmetics, Sulfur

NEW YORK, Oct. 20, 2022 /PRNewswire-PRWeb/ -- ORPHEUS SKIN, the award-winning Bioactive skincare from Bulgaria known for their proprietary Youth-Restoring ORPHEUS Flower Cell Peptide Complex® and non-toxic, bioengineered formulas, has officially completed their skincare portfolio with the launch of the new bioactive amino acid micro-foaming Resurrection Serum Slip Cleanser – an innovative serum-to-foam formula packed with biominerals, antioxidants and adaptogens. The cleanser joins the brand's award-winning Resurrection Collection which includes a toner, essence, serum, and moisturizer. The cleanser will be available on Orpheus-skin.com and Amazon as of today, October 20, 2022 and will retail for $48 MSRP.

Key Points: 
  • NEW YORK, Oct. 20, 2022 /PRNewswire-PRWeb/ -- ORPHEUS SKIN, the award-winning Bioactive skincare from Bulgaria known for their proprietary Youth-Restoring ORPHEUS Flower Cell Peptide Complex and non-toxic, bioengineered formulas, has officially completed their skincare portfolio with the launch of the new bioactive amino acid micro-foaming Resurrection Serum Slip Cleanser an innovative serum-to-foam formula packed with biominerals, antioxidants and adaptogens.
  • The cleanser joins the brand's award-winning Resurrection Collection which includes a toner, essence, serum, and moisturizer.
  • To find out more information on the cleanser and ORPHEUS SKIN, visit the website or follow @Orpheus.Skin on Instagram.
  • ABOUT THE ORPHEUS SKIN RESURRECTION COLLECTION:
    ORPHEUS Resurrection All-In-One Serum ($130) - A radiance-boosting and collagen-building ancient botanical stem-cell concentrate that transforms the overall complexion and texture of even the most tired and stressed skin.

Aravo and Orpheus Cyber Partner to Effectively Manage Third-Party Security Risks

Retrieved on: 
Wednesday, October 19, 2022
Organization, SAN, API, ABAC, GDPR, Intelligence, Risk, Ethics, Orpheus, Information, ESG, Risk management

SAN FRANCISCO and LONDON, Oct. 19, 2022 /PRNewswire-PRWeb/ -- Aravo and Orpheus Cyber today announced the integration of Aravo's solution for third-party risk management and Orpheus Cyber's threat intelligence for cyber risk ratings. With this integration, organizations can enrich InfoSec screenings of their third parties and broaden their decision data to include cyber threat risk ratings.

Key Points: 
  • SAN FRANCISCO and LONDON, Oct. 19, 2022 /PRNewswire-PRWeb/ -- Aravo and Orpheus Cyber today announced the integration of Aravo's solution for third-party risk management and Orpheus Cyber's threat intelligence for cyber risk ratings.
  • "Partnering with Orpheus Cyber provides organizations with the intelligence to safely onboard vendors by knowing their cyber risk posture and be able to mitigate these risks using the Aravo solution."
  • The Aravo integration with Orpheus Cyber refreshes cyber risk ratings at a customer-defined interval allowing risk intelligence data to be used in broader third-party modeling and to surface all data for simplified reporting.
  • Dashboards provide aggregated summaries of risk intelligence, including:
    "Orpheus Cyber is excited to partner with Aravo to help customers continuously monitor the security of their supply chains," said Matt Townsend, vice president of business development at Orpheus Cyber.

Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder

Retrieved on: 
Thursday, August 4, 2022
People, Orpheus, Disorder, Tuberous sclerosis complex tumor suppressors, Disability, Glutamate (neurotransmitter), Patient, Stuttering, Company, Neurodevelopmental disorder, CNS, Pain, Safety, FDA, Seizure, Adolescence, Solution, Work, Insulin resistance, GLOBE, PDE10A, Person, Sofinnova, Central nervous system, Â, Neuron, Trigeminal neuralgia, Tourette syndrome, Employment, Ageing, Polaris Partners, Basimglurant, COFD, Population, Pharmaceutical industry, Biotechnology, MD

Orpheus is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.

Key Points: 
  • Orpheus is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.
  • "Recruiting the first participant is an important step in the clinical investigation of gemlapodect in this indication.
  • "Our main goal is to evaluate the safety and efficacy of gemlapodect as a monotherapy for COFD in adults.
  • Gemlapodect, a PDE10A inhibitor, is currently enrolling a Phase 2a clinical trial in patients with Tourette Syndrome.

Noema Pharma Announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b Study of PDE10A Inhibitor Gemlapodect (NOE-105) in Childhood Onset Fluency Disorder

Retrieved on: 
Monday, June 27, 2022
People, Efficiency, FDA, Patient, Sofinnova, Glutamate (neurotransmitter), Basimglurant, Neurodevelopmental disorder, Polaris Partners, TSC, Biology, Investigational New Drug, GLOBE, CNS, Company, Orpheus, PDE10A, Trigeminal neuralgia, Ageing, Disorder, IND, Disability, Neuron, Seizure, COFD, Tuberous sclerosis complex tumor suppressors, US Foods, Tourette syndrome, Safety, Insulin resistance, Work, Pharmaceutical industry, Noema, Biotechnology, Stuttering, Research, MD

The Orpheus Phase 2b study is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.

Key Points: 
  • The Orpheus Phase 2b study is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.
  • "We have great confidence that gemlapodect will help people who stutter maximize their ability to live life to the fullest."
  • Noema Pharma ( www.noemapharma.com ) is a clinical-stage Biotech company targeting debilitating central nervous system (CNS) indications characterized by imbalanced neuronal networks.
  • Gemlapodect, a PDE10A inhibitor, is currently enrolling a Phase 2a clinical trial in patients with Tourette Syndrome.

Orpheus, by McKinsey, named global leader in procurement analytics by industry analysts, attaining top spot in Spend Matters reviews

Retrieved on: 
Monday, June 27, 2022
Spend, Solution, McKinsey & Company, Goal, Compliance, World, Risk, Organization, Software, Congress, Risk management, Construction, Orpheus

Orpheus' software, which helps organizations optimize external expenditures across operations by analyzing purchasing data streams, received the highest analyst rating among all participants in the Spend Analytics SolutionMap.

Key Points: 
  • Orpheus' software, which helps organizations optimize external expenditures across operations by analyzing purchasing data streams, received the highest analyst rating among all participants in the Spend Analytics SolutionMap.
  • "Organizations are looking for insights that can help position the procurement function as a source of competitive advantage.
  • This, in turn, can drive meaningful returns for the bottom line and accelerate environmental sustainability efforts, which is reinforced by the recognition as a Solutions Leader by Spend Matters."
  • With 69 percent of procurement leaders saying digital and analytics solutions are increasingly valuable to procurement functions, the need for innovative solutions was front and center at World Procurement Congress, in London last week.

Educate 360 Professional Training Partners Acquires Pierian Data

Retrieved on: 
Tuesday, May 4, 2021
Video game consoles, Ancient Greek poetry, Orpheus, Pierian Spring, Xbox 360

b'BOSTON, May 4, 2021 /PRNewswire/ --Educate 360 Professional Training Partners (Educate 360) today announced the acquisition of Pierian Data, Inc., a leading provider of high-quality technology training, with a focus on Python programming language courses, data science courses, and machine learning courses.

Key Points: 
  • b'BOSTON, May 4, 2021 /PRNewswire/ --Educate 360 Professional Training Partners (Educate 360) today announced the acquisition of Pierian Data, Inc., a leading provider of high-quality technology training, with a focus on Python programming language courses, data science courses, and machine learning courses.
  • The acquisition will allow Educate 360 to expand its capabilities to make a broader impact in helping individuals and companies have the right skills and talent in a digitally transforming environment.\nThe CEO of Educate 360, Jason Cassidy, commented: "We are incredibly excited to have Pierian Data as part of Educate 360.
  • "\nPierian founder Jose Portilla, shared his thoughts as well: "I am excited for the next phase of Pierian Data\'s growth with Educate 360.
  • Jose will stay on with Educate 360 as Head of Data Science.\nEducate 360, a portfolio company of investment funds managed by Morgan Stanley Capital Partners, is the professional training partner of choice to improve organizational efficiency and effectiveness, increase cross-functional alignment, and drive results.